Can CVS Differentiate Partial Mole from Placental Mesenchymal Dysplasia?
Yes, chorionic villus sampling (CVS) with molecular genotyping can definitively differentiate a partial hydatidiform mole from placental mesenchymal dysplasia, and should be performed when these conditions are suspected prenatally.
The Critical Genetic Distinction
The key to distinguishing these entities lies in their fundamentally different genetic origins:
- Partial hydatidiform moles (PHM) are almost always diandric triploid (69,XXX, 69,XXY, or 69,XYY), resulting from fertilization of a normal ovum by two sperm 1
- Placental mesenchymal dysplasia (PMD) demonstrates a biparental diploid fetal karyotype, though the placenta may show androgenetic and biparental chimerism 2
CVS with molecular genotyping using short tandem repeat (STR) analysis or quantitative fluorescent PCR (QF-PCR) can identify these distinct genetic patterns prenatally 3, 4. This testing reveals whether the tissue is triploid (confirming PHM) or diploid with biparental inheritance (supporting PMD).
When to Perform CVS
Perform CVS when prenatal ultrasound shows:
- Extensive cystic placental changes with grape-like vesicles
- Placentomegaly with hypoechoic or cystic regions
- Growth-restricted or abnormally formed fetus with thickened, cystic placenta 5
- Markedly elevated maternal serum β-hCG levels
The optimal timing is after 10-11 weeks gestation, when CVS is technically feasible and before placental components merge, which can complicate later diagnosis 6, 7.
The Diagnostic Algorithm
- Initial imaging: Transvaginal ultrasound reveals cystic placental changes
- CVS with molecular testing: Perform STR identifier PCR polymorphic marker analysis on chorionic villi 3
- Interpret genetic results:
- Confirm with p57 immunostaining if available: PHM shows patchy p57 positivity; PMD shows p57 positivity in trophoblasts but negativity in villous stromal cells 1, 8
Critical Management Implications
This distinction is essential for counseling and management because:
- PHM: Requires pregnancy termination in most cases, followed by hCG surveillance for gestational trophoblastic neoplasia (occurs in 0.5-1% of PHM cases) 1
- PMD: May allow pregnancy continuation with intensive monitoring, as many cases result in favorable maternal and fetal outcomes despite increased risks of preterm delivery and fetal complications 2, 7
The risk of postmolar gestational trophoblastic neoplasia does not appear to increase with pregnancy continuation in true twin molar pregnancies, being driven instead by intrinsic trophoblastic biology 7.
Common Diagnostic Pitfalls
Avoid relying solely on ultrasound appearance, as PHM, PMD, complete mole with coexisting fetus, and hydropic abortion can appear similar sonographically 5, 3. Histopathologic evaluation alone can also be challenging, particularly distinguishing PHM from non-molar miscarriage with chromosomal abnormalities 1.
If genetic testing shows digynic triploidy (rare, with two maternal contributions), this represents a non-molar triploidy rather than PHM, though this pattern is exceedingly uncommon in clinical practice 4.
Practical Considerations
When full molecular genotyping is unavailable due to resource limitations, ploidy assessment by fluorescent in situ hybridization, DNA flow cytometry, or conventional karyotyping can still identify triploidy versus diploidy in most cases 4. However, these methods cannot determine parental origin, which is why STR analysis remains the gold standard.
CVS should be performed by experienced operators (ideally completing ≥20 procedures annually) to minimize the procedure-related pregnancy loss risk of approximately 0.5-1% 6.